Ottawa, Canada, November 2005 – Sussex Research Laboratories Inc. (Sussex) and the National Research Council (NRC) of Canada’s Institute for Biological Sciences (NRC-IBS) announced today the formation of a strategic research and development agreement designed to advance certain technologies that offer unique opportunities to exploit carbohydrate-based molecules for drug discovery.
Sussex Research is expanding its glycoproducts commercialization efforts in the area of synthetic oligosaccharides and glycoconjugates by forging a strategic alliance with NRC-IBS. The company will collaborate directly with Dr. Dennis Whitfield of the Glycoconjugates and Tumour Immunology Group at NRC-IBS. Dr. Whitfield is a leader in the development of innovative approaches to carbohydrate-based synthesis. The Whitfield lab focuses on design and development of novel approaches to the synthesis of oligosaccharides for use in the development of carbohydrate-based vaccines and glycotherapeutics.
A major objective of the NRC-Sussex agreement is development of new methodologies suitable for synthesizing specific glycoforms for glycoconjugation of biological molecules. Initial focus is on synthetic strategies for glycosylated amino acids and glycopeptides for use in the preparation and subsequent clinical testing of synthetic vaccines, glycosylated peptides and proteins.
ABOUT THE NRC INSTITUTE FOR BIOLOGICAL SCIENCES: The NRC Institute for Biological Sciences in Ottawa is a team of leading life sciences researchers who are committed to making breakthrough discoveries in immunochemistry and neurobiology and moving subsequent technologies into the marketplace.
ABOUT SUSSEX RESEARCH: Sussex Research assists our pharmaceutical, biotechnology and research partners in drug discovery and development through provision of a portfolio of carbohydrate-enabling products and carbohydrate synthesis solutions for development of molecules that incorporate glycotechnology. Carbohydrates play important roles in biological systems ranging from increasing bioavailability, stability and solubility of biological molecules to enhanced target resolution and extended in vivo half-lives. Sussex products and services enable researchers to explore and exploit glycobiology through facile introduction of carbohydrate recognition elements. Sussex products and custom synthesis services may result in improved therapeutic value generation, extension of product franchises as well as creation of new product pipelines and breakthrough therapeutics for our partners. Visit sussex-research.com for more information.
SHARE THIS ARTICLE ON:
Get product updates and announcements from Sussex Research in your inbox at no charge.
Sussex Research Laboratories Inc. to Exhibit at TIDES USA 2022: Oligonucleotide & Peptide Therapeutics
May 4, 2022
Sussex Research Laboratories Inc. to Exhibit at The American Peptide Symposium 2022 - "Peptide Science at the Summit"
April 26, 2022
Sussex Research Laboratories Inc. / Queen’s University collaboration receives support to develop novel small molecule therapies for COVID-19
May 21, 2020
Sussex Research Laboratories Inc. / Queen’s University collaboration receives Collaborative Research and Development Grant (CRDPJ) to develop synthetic strategies toward Deuterium-labeled pharmaceutical compounds with improved efficacy.
August 22, 2018
Sussex Research Laboratories Inc. acquires Chemaphor Chemical Services from Avivagen
October 13, 2017